Alkermes
expected growth drivers net sales patent life indications alcohol dependence prevention of relapse to dependence following detoxification schizophrenia schizophrenia bipolar i disorder potential launch in current proprietary commercial products proprietary candidate under review june licensed product royalty manufacturing revenue commercialized by biogen relapsing forms of multiple sclerosis launched in under the terms of a settlement and license agreement entered into in with pharmaceuticals alkermes granted a non exclusive license under certain patents covering including the remaining patent covering in the to market and sell a generic formulation of in the beginning sometime in or under certain circumstances subject to paragraph certification related to an anda seeking approval of a generic version a patent infringement lawsuit has been filed against the paragraph filer in response full indication and prescribing information for may be found at full prescribing information for may be found at injectable suspension | Alkermes
Company
Deck Type
Deck date
March 2021
Slide
15 of 144
Similar slides by Alkermes
Investor Day
March 2021
Other recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io